AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03403088 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator: • Group LA-P
Description: to apply Laser (780 nm and 70mW) at the cementum-enamel junction at the teeth affected by sensitivity with the laser device having no effective laser emission, only guided by light
Study NCT03403088 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental: • Group DE
Description: to brush teeth with a blinded dentifrice with 0,45% of stannous fluoride and a soft-bristled manual toothbrush (Johnson \& Johnson®).
Study NCT03403088 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator: • Group DE-P
Description: to brush teeth with a blinded dentifrice with 1500 ppm of available fluoride and a soft-bristled manual toothbrush (Johnson \& Johnson®).
Study NCT03403088 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental: • Group RGI
Description: to apply a thin layer of resin based glass-ionomer product on the cervical surface of the affected teeth affected by sensitivity following the manufacturer instructions.
Study NCT03403088 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental: Group RX
Description: to apply Adper Single Bond Plus Adhesive in accordance with the manufacturer instructions, at the teeth affected by sensitivity product for 20 seconds.
Study NCT02666560 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Auditory Cueing
Description: Auditory cueing set at different frequency rates
Study NCT01050855 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RIC: Distal Campath
Description: Campath, Fludarabine, Melphalan, Cyclosporine, Cellcept (MMF)
Study NCT02881749 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mechlorethamine gel 0.016%
Description: The maintenance period for this study includes one year of weekly mechlorethamine gel 0.016%. This period will not begin until the observation period (30 days) has been completed. During the first week of the maintenance period, patients will apply mechlorethamine gel to the entire body surface daily. After the first week, patients will apply mechlorethamine gel to entire body surface one time per week for the rest of the maintenance period.
Study NCT01701713 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DKI ED2011
Study NCT01701713 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham-TDCS
Study NCT02247258 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azathioprine
Description: See arm/group descriptions
Study NCT02247258 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azathioprine in case of endoscopic recurrence
Description: See arm/group descriptions
Study NCT02247258 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ileocolonoscopy
Description: See arm/group descriptions
Study NCT02247258 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Small bowel follow trough
Description: See arm/group descriptions
Study NCT03554902 — intervention group
Intervention type: PROCEDURE
Intervention: Endoscopic gastric tubulization
Description: Endoscopic gastric tubulization is performed using the CE marked endoscopic suture device Overstitch (Apollo Endosurgery, Austin, Tx. USA).
Study NCT01050855 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RIC:Intermediate Campath
Description: Campath, Fludarabine, Melphalan, Cyclosporine, Cellcept (MMF)
Study NCT01050855 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RIC: Mini Busulfan
Description: Campath, Fludarabine, Busulfan, Cyclosporine, Cellcept (MMF)
Study NCT04857346 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indocyanine green
Description: Single application of PDT will be performed. A diode laser (HELBO®TheraLite - Bredent Medical, Germany) with 670 nm wavelength, power of 150 mW, fluency of 22 J/cm2 and density of 1.1 W/cm2 will be used in this study. Indocyanine-green photosensitizer (Sigm Aldrich, USA) with 0.005% concentration will be used as a photosensitizer which will be applied inside the periodontal pockets in a depth of 3 mm with the help of a blunt needle for 10 s. Laser irradiation will be performed for 60 s using a flexible tip. Laser irradiation will be performed at 2 points each on buccal and lingual with the tip stabilized perpendicular to the gingival tissues.
Study NCT04857346 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Indocyanine green
Description: Single application of PDT will be performed. A diode laser (HELBO®TheraLite - Bredent Medical, Germany) with 670 nm wavelength, power of 150 mW, fluency of 22 J/cm2 and density of 1.1 W/cm2 will be used in this study. Indocyanine-green photosensitizer (Sigm Aldrich, USA) with 0.005% concentration will be used as a photosensitizer which will be applied inside the periodontal pockets in a depth of 3 mm with the help of a blunt needle for 10 s. Laser irradiation will be performed for 60 s using a flexible tip. Laser irradiation will be performed at 2 points each on buccal and lingual with the tip stabilized perpendicular to the gingival tissues.
Study NCT04551794 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Selfapy with therapeutic guidance
Description: The program consists of 9 modules with many interactional exercises. Themes that are addressed in the online-program are for example self-esteem, coping with relapse, establishing a structure for daily life and attention and breathing exercises as well as depression-specific topics such as negative thoughts management and arranging and maintaining social contacts. In addition, participants were able to talk about personal experiences with a therapeutic guide.
Study NCT04551794 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Selfapy with additional peer support
Description: The program consists of 9 modules with many interactional exercises. Themes that are addressed in the online-program are for example self-esteem, coping with relapse, establishing a structure for daily life and attention and breathing exercises as well as depression-specific topics such as negative thoughts management and arranging and maintaining social contacts. In addition, participants were able to participate in exchange with peers via an internal closed forum.
Study NCT04213599 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Coronary intervention
Description: Patients with STEMI undergo coronary intervention
Study NCT02362308 — intervention group
Intervention type: DRUG
Intervention: mineralocorticoid receptor antagonist
Description: Subjects will be treated with a mineralocorticoid receptor antagonist according to standard of care
Study NCT02804412 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: This is the control group with 14 h treatment over 10 workdays.
Study NCT02804412 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CIAT-group
Description: Examine the efficacy of CIAT (30 h over 10 workdays) versus Control-group and communication treatment group.
Study NCT02804412 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: communication treatment group (CTG)
Description: Examine the efficacy of CTG (30h over 10 wokrdays) versus CIAT-group and control group
Study NCT00337376 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rapamune
Description: Dose escalation as follows: 5mg PO, 10mg PO, 20mg PO, 40mg PO
Study NCT00337376 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abraxane
Description: intravenous administration of 100mg/m2 Abraxane over 30 minutes, weekly for three out of four consecutive weeks.
Study NCT03018626 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: rituximab (375 mg/m2) given intravenously (IV) on day 0
Study NCT03018626 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: rituximab (375 mg/m2) given intravenously (IV) on day 0
Study NCT03018626 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etoposide
Description: Etoposide(50 mg/m2) given continuous intravenously (CIV) from day 1-4(96 hours)
Study NCT03018626 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin
Description: Doxorubicin(10 mg/m2) given continuous intravenously (CIV) from day 1-4(96 hours)
Study NCT03018626 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vincristine
Description: Vincristine(0.4 mg/m2) given continuous intravenously (CIV) from day 1-4(96 hours)
Study NCT03018626 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: Cyclophosphamide(750 mg/m2)/dayg IV on days 5
Study NCT03018626 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: prednisone (100 mg) given orally bid on days 1 through to 5.
Study NCT03018626 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: prednisone (100 mg) given orally bid on days 1 through to 5.
Study NCT03018626 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Doxorubicin (75 mg/m2) given intravenously (IV) on day 1,
Study NCT03018626 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide (1,200 mg/m2) given intravenously (IV) on day 1,
Study NCT03018626 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vindesine
Description: Vindesine (2 mg/m2) given on days 1 and 5
Study NCT00559949 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT00559949 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selumetinib
Description: Selumetinib was administered orally as a free base suspension at a dose of 100 mg twice daily for 28-day cycles. Those participants experiencing Common Terminology Criteria for Adverse Events (CTCAE) v3.0 grade 3 toxicity or worse had their dose reduced to 50 mg twice daily and then to 50 mg once daily, if necessary.
Study NCT03465345 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin: The starting dose for Metformin is 850mg once a day, the second dose is 850mg once a day; the third dose level is 850mg twice a day; the fourth dose level is 850mg twice a day. Each dose level lasts for 28 days.
Study NCT03465345 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oligomeric Procyanidin Complex
Description: OPC: The starting dose for OPC is 500mg once a day; the second dose is 1000mg once a day; the third dose level is 1000mg once a day; the fourth dose level is 1500mg once a day. Each dose level lasts for 28 days.
Study NCT04652817 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MMI-22-04-2019
Description: A cross-linked form of the Hyaluronic Acid is used in intradermal injection to augment the labia majora area.
Study NCT04379713 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 20-valent pneumococcal conjugate vaccine
Description: Pneumococcal conjugate vaccine
Study NCT04379713 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 13-valent pneumococcal conjugate vaccine
Description: Pneumococcal conjugate vaccine
Study NCT01044394 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: polyethylene glycol (PEG-ELS) and bisacodyl tablets
Description: 2 liters of PEG-ELS and 10mg of bisacodyl tablets once the morning of the colonoscopy
Study NCT02092337 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: computer-assisted speech training
Study NCT01081340 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social network building intervention
Description: Group support and health education sessions weekly during third trimester and once every two weeks until 6 months postpartum
Study NCT01081340 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Home visit
Description: Three home visits during third trimester and three during postpartum period until 6 months postpartum
Study NCT03942419 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atropine 0.1% Ophthalmic Solution
Description: Atropine 0.1% ophthalmic solution administered with a microdose dispenser
Study NCT03942419 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atropine 0.01% Ophthalmic Solution
Description: Atropine 0.01% ophthalmic solution administered with a microdose dispenser
Study NCT03942419 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Ophthalmic Solution
Description: Placebo ophthalmic solution administered with a microdose dispenser
Study NCT04073017 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Enterade®
Description: Participants will drink an 8 ounce bottle of Enterade® twice a day for 4 weeks
Study NCT04073017 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Functional Assessment of Chronic Illness Therapy for Patients with Diarrhea (version 4.0)
Description: Ancillary studies
Study NCT02666560 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Auditory Cueing
Description: Auditory cueing set at different frequency rates
Study NCT00060125 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tipifarnib
Description: Given orally
Study NCT00060125 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT00293176 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donepezil Hydrochloride
Description: Subects will receive a starting dose of 5 mg orally. Dose-escalation from 5 mg to 10 mg will occur at the Week 9 Visit.
Study NCT00003970 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan hydrochloride
Description: Given IV
Study NCT01480089 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intraperitoneal Ropivacaine (AIR)
Description: Ropivacaine 2 mg/kg per lean body mass up to no more than 200mg total dose will be atomized and delivered into the peritoneal cavity at the completion of surgery.
Study NCT01480089 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Atomized Intraperitoneal Saline (AIS)
Description: Atomized saline will be administered to the peritoneal cavity at the completion of surgery.
Study NCT06552494 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: L-mHealth program
Description: The intervention group receiving the L-mHealth program plus care as usual. Data will be collected at baseline (T0), 1 months (T1) and 3 months (T2) after the intervention.
Study NCT01219699 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BYL719
Description: BYL719 is an oral α-specific phosphatidylinositol-3-kinase (PI3K) inhibitor.
Study NCT01219699 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: In adult patients with advanced solid malignancies whose tumors have an alteration (mutation or amplification) of the PIK3CA gene.~Fulvestrant is an estrogen receptor antagonist, administered by monthly intramuscular injection
Study NCT03045419 — intervention group
Intervention type: PROCEDURE
Intervention: gadoxetic acid-enhanced liver MRI
Description: liver MRI using a standard dose (0.025mmol/kg) of gadoxetic acid
Study NCT03977116 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SLGT2
Description: These patients will receive SLGT2 therapy after catheter ablation.
Study NCT03977116 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: These patients will receive placebo therapy after catheter ablation.
Study NCT02219919 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Surgical Group
Description: The surgical group will receive a surgical procedure consisting of the decompression and release of the median nerve at the carpal tunnel performed by an experienced surgeon according to standardized protocols.
Study NCT02219919 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Therapy Group
Description: The physical therapy group will receive 3 treatment sessions of manual therapy including desensitization maneuvers of the central nervous system of 30 minutes of duration, once per week.
Study NCT01606163 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GC1102
Description: 1. Description: GC1102 IV bolus injection during 10\~ 30 seconds.~2. Amount: group1-3ml, group2-5ml, group3-8ml~3. Subject number: group1-8, group2-8, group3-8~4. Administration time: 1day, 2day, 3day, 4day, 5day, 6day, 7day(total: 7 times)
Study NCT01606163 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: JW normal saline
Description: 1. Description: Normal saline IV bolus injection through 10\~ 30 seconds.~   * Each 3 subjects of this placebo comparator group will match with group 1,2,3 respectively. Placebo comparator subjects in each group will be treated with same condition of each group(group 1, group 2, group 3) except being administered JW normal saline.~2. Subject number: 9~3. Administration time: 1day, 2day, 3day, 4day, 5day, 6day, 7day(total: 7 times)
Study NCT03861169 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transluminal viscoelastic delivery and trabeculotomy
Description: Ab-interno transluminal viscoelastic delivery and trabeculotomy using OMNI Surgical System
Study NCT04365400 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DS102
Description: DS102 Epeleuton capsules
Study NCT04365400 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules
Study NCT00509769 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab emtansine [Kadcyla]
Description: Trastuzumab emtansine was provided in either a liquid or a lyophilized formulation.
Study NCT01412034 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CER-001
Description: Biweekly infusion
Study NCT00630188 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: You Decide
Description: For Patients: Video-based decision aid on prostate cancer screening, One-on-One values clarification session with research assistant, One-on-One coaching session with research assistant to encourage good interaction with clinician~For Physicians: a one-time educational session on prostate cancer and the value of shared decision making
Study NCT00630188 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Reducing Your Risks in the Crash
Description: Publicly available video on highway safety and reducing individual risks in a crash
Study NCT01335932 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV Ganciclovir
Description: For first 5 days, dosing of intravenous ganciclovir is 10 mg/kg daily, given as 5 mg/kg every 12 hours (adjusted for renal function). After first 5 days (up to 28 days) IV ganciclovir 5 mg/kg QD ( adjusted for renal function). A minimum interval of 6 hours is required between the first and second dose.
Study NCT01335932 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: For first 5 days, dosing of intravenous placebo is daily, given every 12 hours. After first 5 days (up to 28 days), IV placebo QD. A minimum interval of 6 hours is required between the first and second dose.~The placebo is an IV solution that does not contain any active medications.
Study NCT06555354 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: miRNA targeted analysis on breast cancer tissues
Description: Total RNA is extracted from tissue sample and selected miRNA quantified by PCR based relative quantification method (QPCR) with a standard curve.
Study NCT06555354 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: miRNA targeted analysis on plasma samples
Description: miRNAs extracted from plasma samples are analysed by QPCR and/or ddPCR .
Study NCT06555354 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: miRNA profiling of breast cancer tissues
Description: Selected samples from the retrospective cohort are profiled for miRNA expression by using GeneChip® miRNA 4.0 Array.
Study NCT01998555 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: CBT
Study NCT02573818 — intervention group
Intervention type: DEVICE
Intervention: SEDASYS System
Description: propofol sedation with the SEDASYS System
Study NCT02309580 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Ibrutinib will be administered once daily continuously until disease progression (confirmed by two assessments for CTCL patients only) or intolerance. The dose levels for the Phase 1 portion of the study. Either 560 mg (4 X 140 mg capsules) or 840 mg (6 X 140 mg capsules) doses will be administered. After the recommended expansion dose is established, an expansion cohort of 12 additional patients will be treated at the recommended expansion dose to further characterize the safety at that dose and to further assess preliminary efficacy
Study NCT00436644 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lapatinib
Description: 1250 mg orally days 1 -28.
Study NCT00436644 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topotecan
Description: 3.2 mg/m2 IV over 30 min in 100mL D5W (5% dextrose in water) or 0.9% NS at days 1, 8 \& 15.
Study NCT00261053 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: i.v. recombinant human C1 inhibitor
Study NCT01306513 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: autologous bone marrow derived mesenchymal stromal cells
Description: Intravenous administration of autologous bone marrow-derived mesenchymal stromal cells.
Study NCT02785718 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Global Haemostasis assays
Study NCT02015741 — intervention group
Intervention type: DEVICE
Intervention: EEG monitoring with Bispectral Index and NeuroSENSE
Study NCT02015741 — intervention group
Intervention type: BEHAVIORAL
Intervention: Clinical observation
Description: Patients will be observed during awake periods and during natural sleep.